Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP), which is defined as the presence of an expanded somatic blood-cell clone in persons without other hematologic abnormalities, is common among older persons and is associated with an increased risk of hematologic cancer. We previously found preliminary evidence for an association between CHIP and atherosclerotic cardiovascular disease, but the nature of this association was unclear. METHODS: We used whole-exome sequencing to detect the presence of CHIP in peripheral-blood cells and associated such presence with coronary heart disease using samples from four case-control studies that together enrolled 4726 participants with coronary heart disease and 3529 controls. To assess causality, we perturbed the function of Tet2, the second most commonly mutated gene linked to clonal hematopoiesis, in the hematopoietic cells of atherosclerosis-prone mice. RESULTS: In nested case-control analyses from two prospective cohorts, carriers of CHIP had a risk of coronary heart disease that was 1.9 times as great as in noncarriers (95% confidence interval [CI], 1.4 to 2.7). In two retrospective case-control cohorts for the evaluation of early-onset myocardial infarction, participants with CHIP had a risk of myocardial infarction that was 4.0 times as great as in noncarriers (95% CI, 2.4 to 6.7). Mutations in DNMT3A, TET2, ASXL1, and JAK2 were each individually associated with coronary heart disease. CHIP carriers with these mutations also had increased coronary-artery calcification, a marker of coronary atherosclerosis burden. Hypercholesterolemia-prone mice that were engrafted with bone marrow obtained from homozygous or heterozygous Tet2 knockout mice had larger atherosclerotic lesions in the aortic root and aorta than did mice that had received control bone marrow. Analyses of macrophages from Tet2 knockout mice showed elevated expression of several chemokine and cytokine genes that contribute to atherosclerosis. CONCLUSIONS: The presence of CHIP in peripheral-blood cells was associated with nearly a doubling in the risk of coronary heart disease in humans and with accelerated atherosclerosis in mice. (Funded by the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“That subjects with clonal hematopoiesis are more susceptible to develop nonhematological, most notably cardiovascular, disease”
From Aging of hematopoietic stem cells (2018) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These findings are supported by recent findings demonstrating a causal link between mutations in HSPCs in the context of clonal hematopoiesis with indeterminate origin and altered transcriptional output of macrophages, which affect the vascular wall and contributes to atherosclerosis.83,84”
From Inflammatory bone marrow microenvironment (2019) · cites this paper as [83]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As CHIP-associated mutations are known to alter the development and function of myeloid cells”
From Clonal hematopoiesis is associated with protection from Alzheimer’s disease (2023) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tet2 and Ppm1d mutant murine models have demonstrated an increased inflammatory signature in mutant macrophages, with heightened inflammatory cytokine production upon pro-inflammatory stimulation in vitro [31,32,69,70].”
From Clonal hematopoiesis and inflammation – the perpetual cycle (2023) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated IL-8 and IL-1β levels have been reported in patients with TET2 CH in the Pakistan Risk of Myocardial Infarction Study (PROMIS) [20,32]”
From Clonal hematopoiesis and inflammation – the perpetual cycle (2023) · cites this paper as [32]
Experimental — accuracy not yet measured
38 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Self-citationClonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Self-citationMacrophages in atherosclerosis: a dynamic balance
Moore, K. J., Sheedy, F. J., & Fisher, E. A. (2013) · Nature reviews. Immunology · doi:10.1038/nri3520 · Cited by 2,559
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
Steensma, D. P., Bejar, R., Jaiswal, S., Lindsley, R. C., Sekeres, M. A., Hasserjian, R. P., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-03-631747 · Cited by 1,971
Self-citationAge-related mutations associated with clonal hematopoietic expansion and malignancies
Xie, M., Lu, C., Wang, J., McLellan, M. D., Johnson, K. J., Wendl, M. C., McMichael, J. F., Schmidt, H. K., Yellapantula, V., Miller, C. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3733 · Cited by 1,874
Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
Fuster, J. J., MacLauchlan, S., Zuriaga, M. A., Polackal, M. N., Ostriker, A. C., Chakraborty, R., Wu, C.-L., Sano, S., Muralidharan, S., Rius, C., et al. (2017) · Science · doi:10.1126/science.aag1381 · Cited by 1,536
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
Shlush, L. I., Zandi, S., Mitchell, A., Chen, W. C., Brandwein, J. M., Gupta, V., Kennedy, J. A., Schimmer, A. D., Schuh, A. C., Yee, K. W., et al. (2014) · Nature · doi:10.1038/nature13038 · Cited by 1,443
Ishibashi, S., Brown, M. S., Goldstein, J. L., Gerard, R. D., Hammer, R. E., & Herz, J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116663 · Cited by 1,354
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339
Cited by
Items 601–700 of 1,015
Berger, G., Kroeze, L. I., Koorenhof‐Scheele, T. N., de Graaf, A. O., Yoshida, K., Ueno, H., Shiraishi, Y., Miyano, S., van den Berg, E., Schepers, H., et al. (2018) · Blood · doi:10.1182/blood-2017-09-805879 · Cited by 45
“…that the presence of CHIP in PBSCs is associated with a signi fi cantly increased incidence of nonrelapse mortality, in particular of cardiovascular events, 3,5,15,31 which suggests that CHIP might be a useful prognostic biomarker for the long-term follow-up of patients who have undergone ASCT.”
BackgroundThe Clinical Challenge of Clonal Hematopoiesis, a Newly Recognized Cardiovascular Risk Factor
Sidlow, R., Lin, A. E., Gupta, D., Bolton, K. L., Steensma, D. P., Levine, R. L., Ebert, B. L., & Libby, P. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1271 · Cited by 44
Self-citationWhat To Tell Your Patient With Clonal Hematopoiesis And Why: Insights From Two Specialized Clinics
Steensma, D. P., & Bolton, K. L. (2020) · Blood · doi:10.1182/blood.2019004291 · Cited by 14
Castiglione, M. A., Jiang, Y., Mazzeo, C., Lee, S., Chen, J., Kaushansky, K., Yin, W., Lin, R. Z., Zheng, H., & Zhan, H. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15095 · Cited by 48
“49 We measured the levels of interleukin-1 β (IL-1 β ) and interleukin-6 (IL-6), two proinflammatory cytokines strongly implicated in promoting CVDs. 7,32,33,37,38,50 Consistent with the increased inflammatory monocytes (Ly-6C high ) in Tie2FF1 mice (Figure 1E), IL-1 β mRNA level was significantly upregulated in JAK2V…”
InfluentialLarge-scale Identification of Clonal Hematopoiesis and Mutations Recurrent in Blood Cancers
Feusier, J. E., Arunachalam, S., Tashi, T., Baker, M. J., Vansant-Webb, C. H., Ferdig, A., Welm, B. E., Rodríguez-Flores, J. L., Ours, C., Jorde, L. B., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0094 · Cited by 48
“We calculated the proportion of hotspots in our general CHIP calls at a gene level and overall level, and similarly computed these rates on the data of previously published cohorts (5, 10).”
BackgroundMethodInfluentialAge acquired skewed X chromosome inactivation is associated with adverse health outcomes in humans
Roberts, A. L., Morea, A., Amar, A., Zito, A., Moustafa, J. S. E.-S., Tomlinson, M., Bowyer, R. C. E., Zhang, X., Christiansen, C., Costeira, R., et al. (2022) · eLife · doi:10.7554/elife.78263 · Cited by 46
Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing
Fairchild, L., Whalen, J., D’Aco, K., Wu, J., Gustafson, C. B., Solovieff, N., Su, F., Leary, R. J., Campbell, C. D., & Balbin, O. A. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abm8729 · Cited by 50
“CH status is correlated with increased expression of inflammation gene signatures in the tumor and TME CHIP status, particularly TET2 or DNMT3A mutation, in individuals without cancer has been correlated with increased systemic inflammation markers such as circulating interleukin-6 (IL-6) (23) and IL-8 as well as incr…”
BackgroundClinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients
Panagiota, V., Kerschbaum, J. F., Penack, O., Stein, C. M., Arends, C. M., Koenecke, C., Strzelecka, P. M., Kloos, A., Wiegand, L., Lasch, A., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000957 · Cited by 46
Clonal hematopoiesis and its impact on the aging osteo-hematopoietic niche
Winter, S., Götze, K. S. S., Hecker, J. S., Metzeler, K. H., Guezguez, B., Woods, K., Medyouf, H., Schäffer, A., Schmitz, M., Wehner, R., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02226-6 · Cited by 48
“It is interesting that “ DTA ” genes appear to confer a similar risk of coronary heart disease despite their different biology [13].”
BackgroundResultAnti-ageing interventions for the treatment of cardiovascular disease
Abdellatif, M., Schmid, S., Fuerlinger, A., & Kroemer, G. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae177 · Cited by 52
Palomo, L., Ibáñez, M., Abáigar, M., Vázquez, I., Álvarez, S., Cabezón, M., Tazón‐Vega, B., Rapado, I., Fuster‐Tormo, F., Cervera, J., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16175 · Cited by 51
“…are at a higher risk of developing a myeloid malignancy compared to those individuals with CHIP not presenting any cytopenia, especially in the presence of two or more mutations or if a single mutation in a splicing gene is detected (Arber et al, 2016; Bejar, 2017; Jaiswal et al, 2017) (Table IV).”
BackgroundZaha, V. G., Hayek, S. S., Alexander, K. M., Beckie, T. M., Hundley, W. G., Kondapalli, L., Ky, B., Leger, K. F., Meijers, W. C., Moslehi, J. J., et al. (2021) · Circulation · doi:10.1161/cir.0000000000001032 · Cited by 49
Age as a risk factor in vasculitis
Gloor, A. D., Berry, G. J., Goronzy, J. J., & Weyand, C. M. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00911-1 · Cited by 47
“Also, recent evidence that clonal hematopoiesis is a strong risk factor for atherosclerotic disease emphasizes the pathogenic connection between malfunction of myeloid immune cells and inflammation in the atherosclerotic plaque [5-7].”
Effects of lifestyle factors on leukocytes in cardiovascular health and disease
Janssen, H., Koekkoek, L. L., & Świrski, F. K. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00931-w · Cited by 48
Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy
Kanagal‐Shamanna, R., Beck, D. B., & Calvo, K. R. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051222-122724 · Cited by 51
Homilius, M., Zhu, W., Eddy, S. S., Thompson, P. C., Zheng, H., Warren, C. N., Evans, C. G., Kim, D. D., Xuan, L. L., Nsubuga, C., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01600-x · Cited by 45
“For example, dysregulation of hematopoietic processes can result in disease progression via mechanisms such as the contribution of inflammation to atherosclerosis and insulin resistance 7–9 or hyperactive coagulation in pathological thrombosis 10–12 .”
Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis
Mohammadnia, N., Xue, L., Vestjens, L. T. W., Uddin, M. M., Niroula, A., de Kleijn, D. P. V., Mosterd, A., Fiolet, A. T. L., Nakao, T., Eikelboom, J. W., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.025 · Cited by 48
Self-citationKodali, H., Pavilonis, B., & Schooling, C. M. (2018) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqy129 · Cited by 43
LncRNA XIST promotes myocardial infarction by regulating FOS through targeting miR-101a-3p
Lin, B., Xu, J., Wang, F., Wang, J., Zhao, H., & Feng, D. (2020) · Aging · doi:10.18632/aging.103072 · Cited by 47
“which will help people understand the relationship between genes and diseases [6, 7].”
BackgroundClonal haematopoiesis is increased in early onset in systemic sclerosis
Ricard, L., Hirsch, P., Largeaud, L., Deswarte, C., Jachiet, V., Mohty, M., Rivière, S., Malard, F., Tenon, M., de Vassoigne, F., et al. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa282 · Cited by 44
de Boer, B., Sheveleva, S., Apelt, K., Vellenga, E., Mulder, A. B., Huls, G. A., & Schuringa, J. J. (2020) · Haematologica · doi:10.3324/haematol.2020.254987 · Cited by 48
“It has been shown that hematopoietic clones harboring a pre-leukemia mutation in Tet methylcytosine dioxygenase 2 (TET2) can outgrow non-mutated clones after inflammatory stress, which in turn might be aggravated by the fact that TET2 knockout mice show increased levels of inflammatory proteins including IL1b, IL-6 an…”
BackgroundTerminally Differentiated CD4+ T Cells Promote Myocardial Inflammaging
Delgobo, M., Heinrichs, M., Hapke, N., Ashour, D., Appel, M., Srivastava, M., Heckel, T., Spyridopoulos, I., Hofmann, U., Frantz, S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.584538 · Cited by 43
Mosteo, L., Storer, J. A., Batta, K., Searle, E. J., Duarte, D., & Wiseman, D. H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.635189 · Cited by 45
Clonal hematopoiesis: Molecular and clinical implications
Kusne, Y. N., Xie, Z., & Patnaik, M. M. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106787 · Cited by 47
Urbán, V. S., Ceglédi, A., & Mikala, G. (2022) · GeroScience · doi:10.1007/s11357-022-00698-x · Cited by 45
CHIP‐associated mutant ASXL1 in blood cells promotes solid tumor progression
Liu, X., Sato, N., Shimosato, Y., Wang, T., Denda, T., Chang, Y., Yabushita, T., Fujino, T., Asada, S., Tanaka, Y., et al. (2022) · Cancer Science · doi:10.1111/cas.15294 · Cited by 43
Suthahar, N., Wang, D., Aboumsallem, J. P., Shi, C., de Wit, S., Liu, E. E., Lau, E. S., Bakker, S. J. L., Gansevoort, R. T., van der Vegt, B., et al. (2023) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.10.013 · Cited by 45
“Approximately 29.1% of the participants smoked, 34.7% had hypertension, 5.1% had diabetes, 5.6% had a history of CVD, and 4.2% had a history of cancer (Table 1).”
BackgroundInfluentialClonal haematopoiesis, ageing and kidney disease
Vlasschaert, C., Lanktree, M. B., Rauh, M. J., Kelly, T. N., & Natarajan, P. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00778-x · Cited by 43
“Specifically, Tet2 -CHIP mice had greater macrophage infiltration in the kidneys and glomerulosclerosis than control mice in an atherogenic model 38 .”
Self-citationYu, K., Deuitch, N. T., Merguerian, M., Cunningham, L., Davis, J., Bresciani, E., Diemer, J. L., Andrews, E. T., Young, A., Donovan, F. X., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011165 · Cited by 47
“Large population studies showed that CH increases the risks of atherosclerotic cardiovascular diseases, 12,13 hematologic neoplasms, 11,14 and other nonmalignant diseases.”
BackgroundPasquer, H., Oliveira, R. D. D., Vasseur, L., Soret‐Dulphy, J., Maslah, N., Zhao, L., Marcault, C., Cazaux, M., Gauthier, N., Verger, E., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02114-5 · Cited by 48
“TET2 and DNMT3A are the two most frequently mutated genes in clonal hematopoiesis of indeterminate potential (CHIP) [45].”
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer
Arends, C. M., Kopp, K., Hablesreiter, R., Estrada, N., Christen, F., Moll, U. M., Zeillinger, R., Schmitt, W., Sehouli, J., Kulbe, H., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02253-3 · Cited by 50
“…(CH), characterized by the expansion of somatically mutated hematopoietic stem cells, has emerged as a prevalent phenomenon associated with the development of hematologic malignancies [1 – 4], increased cardiovascular risk [5, 6] and other age-related pro-in fl ammatory conditions [7 – 11].”
BackgroundMolinaro, R., Sellar, R. S., Vromman, A., Sausen, G., Folco, E. J. E., Sukhova, G. K., McConke, M. E., Corbo, C., Ebert, B. L., & Libby, P. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132184 · Cited by 44
Self-citationTherapeutic genome editing in cardiovascular diseases
Nishiga, M., Qi, L. S., & Wu, J. C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.02.003 · Cited by 44
“For blood cells, an ex vivo strategy might be applicable to immune cells to improve chronic inflammation for the prevention of atherosclerosis [72, 73].”
BackgroundMutations in normal tissues—some diagnostic and clinical implications
Fiala, C., & Diamandis, E. P. (2020) · BMC Medicine · doi:10.1186/s12916-020-01763-y · Cited by 46
“of 4726 participants with heart disease and 3529 controls linked clonal hematopoiesis with a two times greater incidence of atherosclerosis, a condition characterized by arterial buildups of fat and cholesterol [42].”
BackgroundLeedy, D. J., Reding, K. W., Vasbinder, A. L., Anderson, G. L., Barac, A., Wactawski‐Wende, J., Shadyab, A. H., Eaton, C. B., Levy, W. C., Qi, L., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2207 · Cited by 45
The Genetics of Myelodysplastic Syndromes: Clinical Relevance
Chiereghin, C., Travaglino, E., Zampini, M., Saba, E., Saitta, C., Riva, E., Bersanelli, M., & Porta, M. G. D. (2021) · Genes · doi:10.3390/genes12081144 · Cited by 46
Tumor-Based Genetic Testing and Familial Cancer Risk
Forman, A. D., & Sotelo, J. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036590 · Cited by 43
“2017), and CHIP has also been associated with acute cardiovascular events (Jaiswal et al. 2017).”
BackgroundInfluentialMayerhofer, E., Strecker, C., Becker, H., Georgakis, M. K., Uddin, M. M., Hoffmann, M. M., Nadarajah, N., Meggendorfer, M., Haferlach, T., Rosand, J., et al. (2023) · Stroke · doi:10.1161/strokeaha.122.041416 · Cited by 41
Self-citationJin, F., Li, J., Guo, J., Doeppner, T. R., Hermann, D. M., Yao, G., & Dai, Y. (2021) · European Heart Journal Open · doi:10.1093/ehjopen/oeab022 · Cited by 41
“73 Notably, DNMT3A represents one of the most commonly mutated genes in coronary heart disease (CHD) patients carrying CHIP.”
BackgroundInfluentialBone marrow inflammatory memory in cardiometabolic disease and inflammatory comorbidities
Mitroulis, I., Hajishengallis, G., & Chavakis, T. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad003 · Cited by 47
“…of bone marrow cells from Tet2 − / − mice into Ldlr − / − mice resulted in enhanced atherosclerosis, kidney glomerulosclerosis, and inflammatory infiltrates in the liver, 118 suggesting that Tet2 -deficient clones accelerate the inflammatory process related to cardiometabolic disease.”
BackgroundResultInfluentialAge at Menopause, Leukocyte Telomere Length, and Coronary Artery Disease in Postmenopausal Women
Schuermans, A., Nakao, T., Uddin, M. M., Hornsby, W., Ganesh, S., Shadyab, A. H., Liu, S., Haring, B., SHUFELT, C. L., Taub, M. A., et al. (2023) · Circulation Research · doi:10.1161/circresaha.123.322984 · Cited by 46
“9,11 These findings suggest that somatic (acquired) genomic phenomena may play a significant role in linking reproductive aging with cardiovascular disease.”
BackgroundSelf-citationClonal Hematopoiesis of Indeterminate Potential From a Heart Failure Specialist's Point of View
Sikking, M. A., Stroeks, S. L. V. M., Waring, O. J., Henkens, M. T. H. M., Riksen, N. P., Hoischen, A., Heymans, S. R. B., & Verdonschot, J. A. J. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030603 · Cited by 44
“2,72 Three mechanisms are important in the interaction between CHIP and ASCVD: (1) CHIP upregulates the inflammasome/IL-1/IL-6 pathway (Figures 1 and 3).”
InfluentialCoffee, B. W., Cox, H. C., Bernhisel, R., Manley, S., Bowles, K. R., Roa, B. B., & Mancini‐DiNardo, D. (2019) · Human Mutation · doi:10.1002/humu.23910 · Cited by 43
“…somatically through CHIP do not carry hereditary cancer risk, though they are associated with other risks such as hematologic cancer, cardiovascular disease, and all‐cause mortality (Genovese et al., 2014; Gillis et al., 2017; Jaiswal et al., 2014; Jaiswal et al., 2017; Takahashi et al., 2017).”
BackgroundRed Cell Distribution Width Is a Risk Factor for Hip Fracture in Elderly Men Without Anemia
Kim, K. M., Lui, L., Cauley, J. A., Ensrud, K. E., ORWOLL, E. S., Schousboe, J. T., & Cummings, S. R. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3963 · Cited by 41
“Because of disturbed hematopoiesis with CH, RBC size is varied with CH.((27)) Therefore, higher RDW might reflect disturbed hematopoiesis with aging-related CH.”
BackgroundInfluentialMetabolic Consequences of Efferocytosis and Its Impact on Atherosclerosis
Yurdagul, A. (2021) · Immunometabolism · doi:10.20900/immunometab20210017 · Cited by 42
Lötscher, F., Seitz, L., Simeunovic, H., Sarbu, A.-C., Porret, N. A., Feldmeyer, L., Borradori, L., Bonadies, N., & Maurer, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.800149 · Cited by 44
“In MDS, the prognostic significance of driver mutations is undisputed, but the prognostic impact of dysimmune/autoinflammatory manifestations continues to be debated (5, 14, 18, 19).”
BackgroundSingle-cell technologies to decipher cardiovascular diseases
Abplanalp, W. T., Tucker, N. R., & Dimmeler, S. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac095 · Cited by 43
“Somatic mutations leading to clonal haematopoiesis of indeterminate potential (CHIP) promote atherosclerosis and the progression of heart failure.(60,61) While more insights are needed to assess whether CHIP is a novel risk factor or may be a therapeutic target for precision treatment, a few studies provide insights a…”
Somatic genetic alterations predict hematological progression in GATA2 deficiency
Largeaud, L., Collin, M., Monselet, N., Vergez, F., Fregona, V., Larcher, L., Hirsch, P., Duployez, N., Bidet, A., Luquet, I., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.282250 · Cited by 46
Clonal hematopoiesis and preleukemia—Genetics, biology, and clinical implications
Hartmann, L., & Metzeler, K. H. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22756 · Cited by 47
Rayes, H., Vallabhajosyula, S., Barsness, G. W., Anavekar, N. S., Go, R. S., Patnaik, M. M., KASHANI, K. B., & Jentzer, J. C. (2019) · Clinical Research in Cardiology · doi:10.1007/s00392-019-01549-0 · Cited by 44
“An elevated MCV may represent myelodysplastic syndrome or clonal hematopoiesis of indeterminate potential (CHIP), the latter of which has been associated with an increased risk of cardiovascular events and highlighted as a potent emerging cardiovascular risk factor [31, 32].”
BackgroundStauder, R., Augschoell, J., Hamaker, M. E., & Koinig, K. A. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000332 · Cited by 45
Active DNA demethylation—The epigenetic gatekeeper of development, immunity, and cancer
Prasad, R. M., Yen, T. J., & Bellacosa, A. (2020) · Advanced Genetics · doi:10.1002/ggn2.10033 · Cited by 48
Martin, E. C. S., Ferrer, A., Mangaonkar, A. A., Khan, S. P., Kohorst, M. A., Joshi, A. Y., Hogan, W. J., Olteanu, H., Moyer, A. M., Al‐Kali, A., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26321 · Cited by 40
An interferon gamma response signature links myocardial aging and immunosenescence
Ashour, D., Rebs, S., Arampatzi, P., Saliba, A.-E., Dudek, J., Schulz, R., Hofmann, U., Frantz, S., Cochain, C., Streckfuß-Bömeke, K., et al. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad068 · Cited by 39
“7 These changes in the immune system, with increased baseline low-grade inflammation, have been termed ‘inflamma-ging’ 3 and have been associated to worsened response to infection, 8 and reduced vaccine efficacy.”
BackgroundIschaemic heart disease in patients with cancer
Ameri, P., Bertero, E., Lombardi, M., Porto, I., Canepa, M., Nohria, A., Vergallo, R., Lyon, A. R., & López‐Fernández, T. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae047 · Cited by 40
Adaptive immunity and atherosclerosis: aging at its crossroads
Snijckers, R., & Foks, A. C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1350471 · Cited by 40
“Notably, Jaiswal et al. have con fi rmed a 1.9-fold elevated risk of coronary artery disease in carriers of CHIP compared to non-carriers alongside an increase in coronary artery calci fi cation and a 4-fold greater risk for early onset myocardial infarction (80).”
InfluentialGenomics of therapy-related myeloid neoplasms
Kuzmanovic, T., Patel, B. J., Sanikommu, S. R., Nagata, Y., Awada, H. K., Kerr, C. M., Przychodzen, B. P., Jha, B. K., Hiwase, D., Singhal, D., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.219352 · Cited by 42
Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia
Awad, S. A., Kankainen, M., & Mustjoki, S. M. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1894652 · Cited by 42
Dillon, L. W., Ghannam, J. Y., Nosiri, C., Gui, G., Goswami, M., Calvo, K. R., Lindblad, K. E., Oetjen, K. A., Wilkerson, M. D., Soltis, A. R., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0046 · Cited by 40
Unknown/enigmatic functions of extracellular ASC
de Souza, J. G., Starobinas, N., & Ibañez, O. M. (2021) · Immunology · doi:10.1111/imm.13375 · Cited by 48
“A likely role of eASC specks in these pathologies deserves to be investigated [51].”
BackgroundShin, T., Zhou, Y., Chen, S., Cordes, S., Grice, M. Z., Fan, X., Lee, B., Aljanahi, A. A., Hong, S. G., Vaughan, K. L., et al. (2022) · Blood · doi:10.1182/blood.2021014875 · Cited by 40
Retrospective analysis of somatic mutations and clonal hematopoiesis in astronauts
Brojakowska, A., Kour, A., Thel, M. C., Park, E., Bisserier, M., Garikipati, V. N. S., Hadri, L., Mills, P. J., Walsh, K. X., & Goukassian, D. A. (2022) · Communications Biology · doi:10.1038/s42003-022-03777-z · Cited by 43
Clonal hematopoiesis and cardiovascular disease: deciphering interconnections
Stein, A., Metzeler, K. H., Kubasch, A. S., Rommel, K., Desch, S., Buttner, P. G., Rosołowski, M., Cross, M. A., Platzbecker, U., & Thiele, H. (2022) · Basic Research in Cardiology · doi:10.1007/s00395-022-00969-w · Cited by 43
“In the meantime, however, there is increasing evidence that CH clones well below 2% VAF can also impact cardiovascular life time [13, 54, 55].”
BackgroundResultInfluentialGalli, M., Abbate, A., Bonaca, M. P., Crea, F., Forte, M., Frati, G., Gaudino, M. F. L., Gibson, C. M., Gorog, D. A., Mehran, R., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01249-z · Cited by 52
“Accordingly, in an exploratory analysis of the CANTOS trial 468 , among patients with TET2 -related CHIP, those who received canakinumab had a lower rate of cardiovascular events than those in the placebo group, supporting the notion that the effects of TET2 mutations are mediated via IL-1β and IL-6 signalling, and th…”
InfluentialSelf-citationThe year in cardiology 2018: heart failure
Cleland, J. G. F., van Veldhuisen, D. J., & Ponikowski, P. P. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz010 · Cited by 42
“Greater age, those on more treatment for heart failure, higher plasma NT-proBNP (median [interquartile range]: 72 [44-147]ng/L) and worse global longitudinal strain predicted a greater propensity to relapse but pathological variants in the titin gene did not.”
BackgroundIs Hematopoietic Clonality of Indetermined Potential a Risk Factor for Pulmonary Embolism?
Jedraszak, G., Soudet, S., Evrard, O., Marolleau, J., Garçon, L., & Sevestre, M. (2021) · TH Open · doi:10.1055/s-0041-1733856 · Cited by 40
Wang, Y., Gao, H., Wang, F., Ye, Z., Mokrý, M., Turner, A. W., Ye, J., Koplev, S., Luo, L., Alsaigh, T., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab347 · Cited by 41
Somatic mutations in rheumatological diseases: VEXAS syndrome and beyond
Sikora, K. A., Wells, K. V., Bölek, E. Ç., Jones, A. I., & Grayson, P. C. (2021) · Rheumatology · doi:10.1093/rheumatology/keab868 · Cited by 43
Marongiu, F., & DeGregori, J. V. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13275 · Cited by 43
Management of patients with lower-risk myelodysplastic syndromes
Brunner, A. M., Leitch, H. A., van de Loosdrecht, A. A., & Bonadies, N. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00765-8 · Cited by 43
“Clonal cytopenia of undetermined significance (CCUS; cytopenias with clonal mutation, but not meeting MDS diagnostic criteria), idiopathic cytopenia of uncertain significance (ICUS; cytopenias without a clonal mutation detected), and idiopathic dysplasia of unknown significance (IDUS; bone marrow dysplasia without a c…”
MethodA New Therapeutic Framework for Atrial Fibrillation Drug Development
Ang, Y.-S., Rajamani, S., Haldar, S. M., & Hüser, J. (2020) · Circulation Research · doi:10.1161/circresaha.120.316576 · Cited by 41
Dietary interventions as regulators of stem cell behavior in homeostasis and disease
Novak, J. S. S., Baksh, S. C., & Fuchs, E. V. (2021) · Genes & Development · doi:10.1101/gad.346973.120 · Cited by 40
“Consistently, abnormal myelopoiesis can exacerbate metabolic disease: In both patients and mice, enhanced inflammatory signaling in clonally expanded HSCs and their myeloid daughter cells accelerates atherosclerosis under a Western diet (Fuster et al. 2017; Jaiswal et al. 2017).”
BackgroundBruserud, Ø., Vo, A. K., & Reikvam, H. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030706 · Cited by 43
“Patients with clonal hematopoiesis have an increased risk of atherosclerosis and cardiovascular complications [12,30,31].”
BackgroundA Single Nucleotide Polymorphism in SH2B3/LNK Promotes Hypertension Development and Renal Damage
Alexander, M. R., Hank, S., Dale, B. L., Himmel, L. E., Zhong, X. Y., Smart, C. D., Fehrenbach, D. J., Chen, Y., Prabakaran, N., Tirado, B. A., et al. (2022) · Circulation Research · doi:10.1161/circresaha.121.320625 · Cited by 41
Forged in the fire: Lasting impacts of inflammation on hematopoietic progenitors
Cao, R., Thatavarty, A., & King, K. Y. (2024) · Experimental Hematology · doi:10.1016/j.exphem.2024.104215 · Cited by 39
Gallucci, G., Turazza, F. M., Inno, A., Canale, M. L., Silvestris, N., Farì, R., Navazio, A., Pinto, C., & Tarantini, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084232 · Cited by 41
Liu, W., Hardaway, B. D., Kim, E., Pauli, J., Wettich, J. L., Yalçınkaya, M., Hsu, C.-C., Xiao, T., Reilly, M. P., Tabas, I. A., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci182939 · Cited by 42
“IL-1 β antibodies remain unapproved for CVD indications, and although colchicine was recently approved by the FDA, its therapeutic potential may be limited (7).”
InfluentialStem cells and heart disease - Brake or accelerator?
Steinhoff, G., Nesteruk, J., Wolfien, M., Große, J., Ruch, U., Vasudevan, P., & Müller, P. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.10.007 · Cited by 39
Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes
Ivy, K. S., & Ferrell, P. B. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0463-9 · Cited by 41
Recent advances in therapeutic targeting of inflammation in atherosclerosis
Hedin, U., & Matic, L. P. (2018) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2018.10.051 · Cited by 39
Inflammation and cardiovascular disease
Katsiari, C. G., Bogdanos, D. P., & Sakkas, L. I. (2019) · World Journal of Translational Medicine · doi:10.5528/wjtm.v8.i1.1 · Cited by 40
Karjalainen, R., Liu, M., Kumar, A., He, L., Malani, D., Parsons, A., Kontro, M., Kallioniemi, O., Porkka, K., & Heckman, C. A. (2019) · Leukemia · doi:10.1038/s41375-019-0504-y · Cited by 41
Pathobiology of cardiovascular diseases: an update
Buja, L. M., Giulia Ottaviani, M., & Mitchell, R. N. (2019) · Cardiovascular Pathology · doi:10.1016/j.carpath.2019.06.002 · Cited by 39
Bewersdorf, J. P., Ardasheva, A., Podoltsev, N. A., Singh, A., Biancon, G., Halene, S., & Zeidan, A. M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100587 · Cited by 40
Interplay between Clonal Hematopoiesis of Indeterminate Potential and Metabolism
Lee, M. K. S., Dragoljevic, D., Veiga, C. B., Wang, N., Yvan‐Charvet, L., & Murphy, A. J. (2020) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2020.02.005 · Cited by 39
Okamura, R., Piccioni, D. E., Boichard, A., Lee, S., Jimenez, R. E., Sicklick, J. K., Kato, S., & Kurzrock, R. (2021) · International Journal of Cancer · doi:10.1002/ijc.33481 · Cited by 38
“Previous studies reported that CH is associated with increased all-cause death and shorter OS time, suggesting that the increased death was caused by cardiovascular or ischemic stroke events rather than hematologic malignancies.(16,30,31) Our study also demonstrated that the presence of CH-type mutations in cfDNA was…”
Crucial role of hematopoietic JAK2 V617F in the development of aortic aneurysms
Yokokawa, T., Misaka, T., Kimishima, Y., Wada, K., Minakawa, K., Sugimoto, K., Ishida, T., Morishita, S., Komatsu, N., Ikeda, K., et al. (2021) · Haematologica · doi:10.3324/haematol.2020.264085 · Cited by 40
Watad, ., Kačar, M., Bragazzi, N. L., Zhou, Q., Jassam, M., Taylor, J., Roman, E., Smith, A. G., Jones, R. A., Amital, H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.610019 · Cited by 40
CD200 Limits Monopoiesis and Monocyte Recruitment in Atherosclerosis
Kassiteridi, C., Cole, J. E., Griseri, T., Falck-Hansen, M., Goddard, M. E., Seneviratne, A. N., Green, P., Park, I., Shami, A., Pattarabanjird, T., et al. (2021) · Circulation Research · doi:10.1161/circresaha.119.316062 · Cited by 41
ZBTB33 Is Mutated in Clonal Hematopoiesis and Myelodysplastic Syndromes and Impacts RNA Splicing
Beauchamp, E. M., Leventhal, M. J., Bernard, E., Hoppe, E. R., Todisco, G., Creignou, M., Gallì, A., Castellano, C. A., McConkey, M. E., Tarun, A., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0224 · Cited by 39
“CHIP variant calls were produced using MuTect and Indelocator as previously described (42).”
Self-citationThe paradox of mutations and cancer
Chanock, S. J. (2018) · Science · doi:10.1126/science.aav5697 · Cited by 39
Mitchell, K., & Steidl, U. G. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036251 · Cited by 40
“…associated with increased risk of diseases with inflammatory components, including coronary heart disease and various cancers (Coombs et al. 2017; Jaiswal et al. 2017); thus, a positive feedback loop between an inflammatory microenvironment and the development of and selection for aberrant HSCs…”
BackgroundSato, N., Goyama, S., Chang, Y., Miyawaki, M., Fujino, T., Koide, S., Denda, T., Liu, X., Ueda, K., Yamamoto, K., et al. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00579-w · Cited by 42
Inflammageing and clonal haematopoiesis interplay and their impact on human disease
Hajishengallis, G., & Chavakis, T. (2026) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-025-00936-y · Cited by 40
Slavin, T. P., Coffee, B. W., Bernhisel, R., Logan, J. K., Cox, H. C., Marcucci, G., Weitzel, J. N., Neuhausen, S. L., & Mancini‐DiNardo, D. (2019) · Cancer Genetics · doi:10.1016/j.cancergen.2019.04.005 · Cited by 38
“[1, 2] Many likely-mosaic variants identified in this manner reflect amplification of mutations acquired somatically in blood via clonal hematopoiesis of indeterminate potential (CHIP), which involves the expansion of clonal blood cell subpopulations without other hematologic disease.[3] Variants derived through CHIP…”
BackgroundVascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors
Fleming, M. R., Xiao, L., Jackson, K. D., Beckman, J. A., Barac, A., & Moslehi, J. J. (2021) · Circulation Research · doi:10.1161/circresaha.121.318259 · Cited by 36
Coronary Artery Disease Without Standard Cardiovascular Risk Factors
Yamamoto, K., Natsuaki, M., Morimoto, T., Shiomi, H., Takeji, Y., Yamaji, K., Matsumura‐Nakano, Y., Yoshikawa, Y., Yamamoto, E., Fuki, M., et al. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.10.032 · Cited by 40
Aging and Clonal Behavior of Hematopoietic Stem Cells
Yamashita, M., & Iwama, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23041948 · Cited by 37
“Of note, clonal hematopoiesis is shown to be an independent risk factor for atherosclerotic cardiovascular diseases, and the risk of coronary heart disease is estimated to increase ~two-fold with DNMT3A, TET2 and ASXL1 mutations, and ~10-fold with the JAK2V617F mutation [82].”
BackgroundLDL delivery of microbial small RNAs drives atherosclerosis through macrophage TLR8
Allen, R. M., Michell, D. L., Cavnar, A. B., Zhu, W., Makhijani, N., Contreras, D. M., Raby, C. A., Semler, E. M., DeJulius, C. R., Castleberry, M., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-01030-7 · Cited by 36
Rhee, J., Pillai, R. K., He, T., Bosworth, A., Chen, S., Atencio, L., Oganesyan, A., Peng, K., Guzman, T., Lukas, K., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.4105 · Cited by 38
Self-citation
Metadata
- Authors
- Jaiswal, S., Natarajan, P., Silver, A. J., Gibson, C. J., Bick, A. G., Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D., Baber, U., Mehran, R., Fuster, V., Danesh, J., Frossard, P., Saleheen, D., Melander, O., Sukhova, G. K., Neuberg, D., Libby, P., Kathiresan, S., & Ebert, B. L.
- Affiliations
- Brigham and Women's Hospital (US)
- Broad Institute (US)
- ORCID
- Jaiswal, Siddhartha
- Natarajan, Pradeep
- Silver, Alexander J.
- Gibson, Christopher J.
- Bick, Alexander G.
- McConkey, Marie
- Gupta, Namrata
- Gabriel, Stacey
- Ardissino, Diego
- Baber, Usman
- Mehran, Roxana
- Danesh, John
- Saleheen, Danish
- Melander, Olle
- Sukhova, Galina K.
- Neuberg, Donna
- Libby, Peter
- Kathiresan, Sekar
- Ebert, Benjamin L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-07-13
- Volume
- 377
- Issue
- 2
- Pages
- 111-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6717509
- OpenAlex
- W2628145035
- Cited by
- 2,683
- References
- 37
- Citations by year
- 2026: 303 · 2025: 322 · 2024: 347 · 2023: 338 · 2022: 371 · 2021: 303 · 2020: 263 · 2019: 215 · 2018: 169 · 2017: 44
- FWCI
- 143.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Apollo
- Funders
- Wellcome Trust
- National Institute for Health and Care Research (NF-SI-0512-10165)
- British Heart Foundation (RG/08/014/24067)
- Novo Nordisk Fonden (NNF14OC0009819, NNF13OC0005339)
- Medical Research Council (MR/L003120/1)
- National Heart, Lung, and Blood Institute (R01HL082945, R01HL080472, RC2HL101834, T32HL116324)
- National Human Genome Research Institute (U54HG003067)
- Fogarty International Center (RC1TW008485)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- clonal hematopoiesis of indeterminate potential, atherosclerotic cardiovascular disease, coronary artery disease, myocardial infarction, coronary artery calcification, TET2 mutation, DNMT3A, ASXL1, JAK2, somatic mutations, atherosclerosis, cytokines and chemokines, macrophages, bone marrow transplantation
- MeSH terms
- Animals, Coronary Disease, Hematopoiesis, Hematopoietic Stem Cells, Humans, Mutation, Risk, Case-Control Studies, Sequence Analysis, DNA, Mice, Knockout, Genetic Predisposition to Disease, Atherosclerosis, Mice, Exome, Clonal Evolution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.